Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Someone needs to update the IBOX its all old info. I'm going to try for Moderator here. I am very excited about this medical stock. It has huge potential no doubt!
Okay, sounds good!! Can't wait to hear more about RCLL!
Lets keep it quiet until we are fully loaded. This is why im not posting anywhere else yet shhh :)
I'm going to do some digging and see if I can find more stuff on this gem. Ill post my findings accordingly.
Ya, thats pretty cool stuff man!
Ya, I'll be here bright and early Monday morning!
It shows .0090/ .02 cents. I hope there are enough shares below .02 cents for sale man on Monday!
Would be nice if one of the tv stations broadcasts stuff like this. Well discovery channel. Hmm i think RCLL is about to get discovered soon. Huge upside potential. Some guy said 52 week high was really .55 cents. So if this stock could go there I would be amazed.
Yeah I hub isn't here yet.
66.67% gain on Friday and it actually went around 80% gain when it hit .011 high of day. Only a few people got in this. Wait until its discovered by the masses. I just hope we can load more monday man. This stock is a rare gem.
That's huge. I was watching a documentary on us veterans that have lost limbs. And they were using stem cell technology to regenerate muscle and others stuff. I wish I could find it again it was on discovery.
Wow you did better than me. Congrats :)
Great. Me too. Glad we are in this one early too. RCLL should really go. Monday even my next buy below .02 will be worth a killing at .10 or higher.
By early I mean the bottom low .001x I think RCLL has great potential. I'm curious to see what they are up to these days.
Check out their website. Love what this company does. Regeneration of body organs etc. Can you believe this? Like WOW!
Yeah me to buddy. Made a killing. I got in very early.
Ya, something must be going on with RCLL. Could be interesting next week
Yes it is bro. You know STEM CELL stocks are known to go parabolic in penny land. I saw one go sub penny to .20+ cents! This stock is hidden and people don't know about it. I hope we can load more next week before it catches on peoples radars.
I have to agree. I was trying to get a higher starter position but because its so thin and not many shares to be had I only got part of it filled. Looking for a solid buy order Monday morning. Hope its at a good pps.
Looks like sudden volume. Usually these types of scenerios occur before news. I was in GFM* this week and same thing happened.
That's good. I'm thinking this might be a 40% to 100% gainer Monday, so I'll have to jump in first thing in the morning and with small float this moves like air.
Dang only 26 million float! Wow thats a seriously small float!
That's great. I managed to grab a starter late friday but will be looking to add more. Love the story behind this gem and the small float.
I' m gonna pick up a starter position Monday and see where this goes next week.
Yeah the float is crazy thin. A little volume and this is off to the races.
Wow .55 cents is still good. A move from here even to .10 cents would be impressive. With the small float and the story behind it i think its quite possible imo.
Answered my question lol
It shows that as a 52 week high, but as I recall in my reading, very few shares were sold at a dollar. In researching, I think the highest the stock ever sold(any significant amount) was around 55 cents pps. That said, it is extremely undervalued, the e is now off the end of it, the chart is in full reversal mode. I am averaged in for just under 0.005 (just got in the other day) I fully intend on loading more this coming week.
This one could run and run very big!
GN, get some sleep.
Wow RCLL used to trade as high as $1 dollar at 52 week high! Extremely undervalued STEM CELL STOCK $$$$
Lol. Me too. Just so excited after doing my DD on this medical gem. Good night bro.
Yeah this is true, but I'm hitting the sack.
STEM Cell stocks are expected to go the next level as technology advances. It is a miracle stock in which many lives have been saved. Nothing gets better than that especially knowing your invested in a stock which helps save lives of people.
FLOAT only 26 million. Got to love that.
Yeah and with the float this moves on air.
Absolutely. The best thing here is we have a medical life changing stock here which deals with regeneration of organs etc of the body. Does not get any better than that. Priceless indeed.
This is ture. Look what happened with GFM#. Volume then the pop.
Agreed. Look at RCLL chart. Major reversal here. Float just 26 million and factor in its STEM CELL. Vastly undervalued here. Some STEM CELL stocks have gone sub penny to .10+ cents or higher. This one looks ready to do the same imo.
STEM Cell Stocks are the next generation life changing medical breakthrough. That said expect this stock to breakout in coming days/ weeks. Volume usually follows by good news.
INCREDIBLE STEM CELL STOCK with excellent working website
Website: http://www.regenocell.com
Cardiac Results
Heart scans from one patient reveal that this treatment not only resulted in the formation of new blood vessels but also in the repair of damaged heart tissue with healthy tissue.
Peripheral Artery Disease
The same RCLL adult stem cell treatment can be used to treat peripheral artery disease. In the United Sates, there are over 10 million people suffering from the lack of sufficient blood flow to the
extremities with an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs. The RCLL adult stem cell treatment derived from the patient's blood will be used to treat this disease. Pilot studies have demonstrated that there is new blood vessel formation which saves the patient from what would progress to an amputation. Administration is through multiple injections in the lower part of the limb with peripheral artery disease
RCLL will take this indication through the Food and Drug Administration and European Medicines Agency regulatory process in order to obtain approval to market this treatment in the United States and Europe. The market potential for this product is enormous given the market size, the lack of effective alternatives once vascular surgery no longer provides relief, and the consequence of no alternatives which is amputation.
Interesting chart here. MACD ready to cross 0.0. Should be some movement next week.
Background On RCLL
Heart failure is one of the most detrimental of diseases. Over 65 million people suffer from coronary artery disease which leads to heart attacks. Heart attacks lead to congestive heart failure. Over 5 million people in the United States suffer from congestive heart failure with 500,000 dying from it each year. The mean life expectancy of someone with end stage heart failure is 6 months.
There are therapies to treat congestive heart failure. But there comes a treatment point when the only option may be a heart transplant. Over 25,000 people are on the transplant lists but fewer than 2,500 receive one. The mean life expectancy of a heart transplant recipient is 8 years. A new therapeutic approach to treat this disease is needed.
Stem cell transplantation is an emerging therapeutic approach to treat various diseases. For congestive heart failure, the aim of transplantation is to replace damaged cells and establish new blood vessels to restore contractility and blood supply to the heart. Early efforts showed promise but also demonstrated the difficulty in achieving consistent results.
Stem cells are cells which have the ability to produce other cells identical to themselves or to differentiate into specific cell lineages. With these properties, stem cells play important roles in normal development and in the regeneration and repair of damaged tissue through the ability to differentiate into the type of cell needed for growth or repair.
The adult stem cells and other mature cells extracted from the circulating blood have been selected because of their ability to differentiate into angiogenic precursor cells, or blood vessel forming cells. They are grown in sufficient numbers to have a clinical effect on a patient. When these angiogenic precursor cells are administered to the patient, they are primed to form new blood vessels.
Umbilical cord blood stem cells are also capable of significant differentiation. While not being subject to ethical controversy as embryonic stem cells, they still possess a genome which is different than the patient's genome. Many different choices may get a similarity in genomes but it will never be an identical match to the one person whose umbilical cord blood is being used to create the stem cells.
Adult stem cells are different. They are autologous, meaning that they are derived from the patient for use in that patient. Typical sources of adult stem cells include bone marrow or blood. Any tissue of the patient may be used. Adult stem cells are capable of differentiating into a variety of cell types without a risk of immunological rejection. Adult stem cells do not have the safety concerns associated with embryonic and umbilical cord blood stem cells.
Clinical Results
The mission of RegenoCELL Therapeutics, Inc. is to bring stem cell therapy treatments to the market as quickly as possible. The Company's therapy utilizes a process to identify and process adult stem cells found in a patient's blood. These adult stem cells are grown into large numbers in vitro (outside the body) and then encouraged to differentiate into angiogenic precursor cells or blood vessel forming cells for the treatment of congestive heart failure.
These adult stem cells can also be used for the treatment of other conditions such as peripheral artery disease. Currently congestive heart failure patients cleared for treatment have one-half liter of blood drawn which is sent to the Company's cell processing facility in Israel. After the adult stem cells in the patient's blood have been extracted and grown into large numbers of angiogenic precursor cells, they are sent to Bangkok, Thailand, the Dominican Republic or other locations where importation of the stem cell therapy is permitted for infusion into the patient in a minimally invasive procedure. The stem cell therapy is either delivered through a catheter similar to angioplasty or injected directly into the myocardium. All patients are private pay.
RCLL's primary asset is Regenocell Laboratories, Ltd., a wholly owned Israeli corporation, which is manufacturing the stem cell therapy product used to treat congestive heart failure and peripheral artery disease. Marketing of the stem cell therapy product either directly or through distributors is done by Regenocell, Ltd., a wholly owned Antigua and Barbuda corporation. RCLL's plan to further build its business is to submit an IND to the Food and Drug Administration and its equivalent to the European Medicines Agency to initiate clinical trials in order to apply and obtain approval for the treatment of peripheral artery disease in the United States and Europe. There are over ten million people suffering from the lack of sufficient blood flow to the extremities in the United States and an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs. Pilot studies have demonstrated that there is new blood vessel formation which saves the patient from what would progress to amputation.
RegenoCELL Therapeutics
RegenoCELL Therapeutics, Inc. (OTC BB: RCLL) will be among the first companies to bring stem cell therapy treatments to the market.
Our treatments for Congestive Heart Failure and Peripheral Artery Disease provide hope for patients who have until now been given limited options or none. These revolutionary treatments restore life to our patients.
RCLL is utilizing adult stem cells, those derived from the patient's own blood, which eliminates the ethical and safety concerns associated with embryonic and umbilical cord blood stem cells. Stem cells have the ability to produce other cells identical to themselves or to differentiate into specific cell lineages which can be used in the regeneration and repair of damaged tissue.
About RegenoCELL
The mission of RegenoCELL Therapeutics, Inc. (OTC BB: RCLL) is to bring stem cell therapy treatments to the market as quickly as possible.
Stem cells have the ability to produce other cells identical to themselves or to differentiate into specific cell lineages which can be used in the regeneration and repair of damaged tissue. RCLL is utilizing adult stem cells, those derived from the patient's own blood, which eliminates
the ethical and safety concerns associated with embryonic and umbilical cord blood stem cells.
RCLL's therapy utilizes a process to identify adult stem cells found in a patient's blood. In circulating blood, the numbers of adult stem cells present are less than 1% of 1% of all the cells found in the blood. At the Company's manufacturing operations in Israel, sufficient stem cells are segregated from the half liter of blood drawn from the patient and then rapidly grown from tens of thousands into many millions over a five day period. This occurs in a standard
class 10,000 clean room with the handling of the cells under a class 100 hood.
The adult stem cells and other mature cells extracted from the circulating blood have been selected because of their ability to differentiate into angiogenic precursor cells, or blood vessel forming cells. When these angiogenic precursor cells are administered to the patient, they are primed to form new blood vessels.
Currently congestive heart failure patients cleared for treatment have one-half liter of blood drawn which is sent to the Company's cell processing facility in Israel.
After the adult stem cells in the patient's blood have been extracted and grown into large numbers of angiogenic precursor cells, they are sent to Bangkok, Thailand,
the Dominican Republic and other locations where importation of the autologous stem cell therapy product is permitted for infusion into the patient in a minimally invasive procedure. The stem cell therapy product is either delivered through a catheter or injected directly into the myocardium. All patients are private pay.
RCLL's primary asset is Regenocell Laboratories, Ltd., a wholly owned Israeli corporation, which is manufacturing the stem cell therapy product used to treat congestive heart failure and peripheral artery disease. Marketing of the stem cell therapy product either directly or through distributors is done by Regenocell, Ltd., a wholly owned Antigua and Barbuda corporation.
RCLL's plan to further build its business is to submit an IND to the Food and Drug Administration and its equivalent to the European Medicines Agency to initiate clinical trials in order to apply and obtain approval for the treatment of peripheral artery disease in the United States and Europe. There are over ten million people suffering from the lack of sufficient blood flow to the extremities in the United States and an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs.
Pilot studies have demonstrated that there is new blood vessel formation which saves the patient from what would progress to amputation.
RCLL Business Description
The mission of RCLL is to bring adult stem cell therapy treatments to the market as quickly as possible. Patients with congestive heart failure or peripheral artery disease have half a liter of blood drawn which is shipped to the RCLL production facility. There the patient's stem cells are extracted and grown over five days from tens of thousands into many millions and encouraged to differentiate into angiogenic precursor cells or blood vessel forming cells. The stem cell therapy is then delivered to the patient in a minimally invasive procedure. All patients are private pay.
Contact Info 2 Briar Lane
Natick, MA 01760
Website: http://www.regenocell.com
Phone: 508-647-4065
Email: info@regenocell.com
What are stem cells, and why are they important?
Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.
Stem cells are distinguished from other cell types by two important characteristics. First, they are unspecialized cells capable of renewing themselves through cell division, sometimes after long periods of inactivity. Second, under certain physiologic or experimental conditions, they can be induced to become tissue- or organ-specific cells with special functions. In some organs, such as the gut and bone marrow, stem cells regularly divide to repair and replace worn out or damaged tissues. In other organs, however, such as the pancreas and the heart, stem cells only divide under special conditions.
Until recently, scientists primarily worked with two kinds of stem cells from animals and humans: embryonic stem cells and non-embryonic "somatic" or "adult" stem cells. The functions and characteristics of these cells will be explained in this document. Scientists discovered ways to derive embryonic stem cells from early mouse embryos nearly 30 years ago, in 1981. The detailed study of the biology of mouse stem cells led to the discovery, in 1998, of a method to derive stem cells from human embryos and grow the cells in the laboratory. These cells are called human embryonic stem cells. The embryos used in these studies were created for reproductive purposes through in vitro fertilization procedures. When they were no longer needed for that purpose, they were donated for research with the informed consent of the donor. In 2006, researchers made another breakthrough by identifying conditions that would allow some specialized adult cells to be "reprogrammed" genetically to assume a stem cell-like state. This new type of stem cell, called induced pluripotent stem cells (iPSCs), will be discussed in a later section of this document.
Stem cells are important for living organisms for many reasons. In the 3- to 5-day-old embryo, called a blastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lung, skin, sperm, eggs and other tissues. In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease.
Given their unique regenerative abilities, stem cells offer new potentials for treating diseases such as diabetes, and heart disease. However, much work remains to be done in the laboratory and the clinic to understand how to use these cells for cell-based therapies to treat disease, which is also referred to as regenerative or reparative medicine.
Laboratory studies of stem cells enable scientists to learn about the cells' essential properties and what makes them different from specialized cell types. Scientists are already using stem cells in the laboratory to screen new drugs and to develop model systems to study normal growth and identify the causes of birth defects.
Research on stem cells continues to advance knowledge about how an organism develops from a single cell and how healthy cells replace damaged cells in adult organisms. Stem cell research is one of the most fascinating areas of contemporary biology, but, as with many expanding fields of scientific inquiry, research on stem cells raises scientific questions as rapidly as it generates new discoveries.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
241
|
Created
|
12/26/07
|
Type
|
Free
|
Moderators |
Market Value1 | $491,775 | a/o May 10, 2012 |
Shares Outstanding | 81,962,500 | a/o Nov 15, 2011 |
Float | 26,637,500 | a/o Sep 29, 2010<----- Float ONLY 26 MILLION! |
Authorized Shares | 520,000,000 | a/o Sep 29, 2010 |
Par Value | No Par Value |
Shareholders of Record | 20 | a/o May 16, 2011 |
Ex. Date | Record Date | Pay Date | |
---|---|---|---|
Dividend (0.00) | Apr 02, 2008 | Mar 31, 2008 | Apr 01, 2008 |
|
Short Interest | 40,000 (0%) Apr 30, 2012 |
Significant Failures to Deliver | No |
Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.
Stem cells are distinguished from other cell types by two important characteristics. First, they are unspecialized cells capable of renewing themselves through cell division, sometimes after long periods of inactivity. Second, under certain physiologic or experimental conditions, they can be induced to become tissue- or organ-specific cells with special functions. In some organs, such as the gut and bone marrow, stem cells regularly divide to repair and replace worn out or damaged tissues. In other organs, however, such as the pancreas and the heart, stem cells only divide under special conditions.
Until recently, scientists primarily worked with two kinds of stem cells from animals and humans: embryonic stem cells and non-embryonic "somatic" or "adult" stem cells. The functions and characteristics of these cells will be explained in this document. Scientists discovered ways to derive embryonic stem cells from early mouse embryos nearly 30 years ago, in 1981. The detailed study of the biology of mouse stem cells led to the discovery, in 1998, of a method to derive stem cells from human embryos and grow the cells in the laboratory. These cells are called human embryonic stem cells. The embryos used in these studies were created for reproductive purposes through in vitro fertilization procedures. When they were no longer needed for that purpose, they were donated for research with the informed consent of the donor. In 2006, researchers made another breakthrough by identifying conditions that would allow some specialized adult cells to be "reprogrammed" genetically to assume a stem cell-like state. This new type of stem cell, called induced pluripotent stem cells (iPSCs), will be discussed in a later section of this document.
Stem cells are important for living organisms for many reasons. In the 3- to 5-day-old embryo, called a blastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lung, skin, sperm, eggs and other tissues. In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease.
Given their unique regenerative abilities, stem cells offer new potentials for treating diseases such as diabetes, and heart disease. However, much work remains to be done in the laboratory and the clinic to understand how to use these cells for cell-based therapies to treat disease, which is also referred to as regenerative or reparative medicine.
Laboratory studies of stem cells enable scientists to learn about the cells' essential properties and what makes them different from specialized cell types. Scientists are already using stem cells in the laboratory to screen new drugs and to develop model systems to study normal growth and identify the causes of birth defects.
Research on stem cells continues to advance knowledge about how an organism develops from a single cell and how healthy cells replace damaged cells in adult organisms. Stem cell research is one of the most fascinating areas of contemporary biology, but, as with many expanding fields of scientific inquiry, research on stem cells raises scientific questions as rapidly as it generates new discoveries.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |